Recent Analysts’ Ratings Changes for Bio-Techne (TECH)

Several brokerages have updated their recommendations and price targets on shares of Bio-Techne (NASDAQ: TECH) in the last few weeks:

• 6/23/2026 – Bio-Techne had its “buy” rating reaffirmed by TD Cowen.
• 6/11/2026 – Bio-Techne is now covered by Piper Sandler. They set a “neutral” rating and a $65.00 price target on the stock.
• 6/11/2026 – Bio-Techne is now covered by Piper Sandler. They set a “neutral” rating and a $65.00 price target on the stock.
• 6/8/2026 – Bio-Techne was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/14/2026 – Bio-Techne was given a new $62.00 price target by Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 5/14/2026 – Bio-Techne was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/7/2026 – Bio-Techne was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/7/2026 – Bio-Techne was given a new $50.00 price target by Evercore Inc.
• 5/7/2026 – Bio-Techne was given a new $50.00 price target by Stifel Nicolaus.
• 5/7/2026 – Bio-Techne was given a new $49.00 price target by Robert W. Baird.
• 5/7/2026 – Bio-Techne had its price target lowered by Citigroup Inc. from $80.00 to $70.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Bio-Techne had its price target lowered by Wells Fargo & Company from $76.00 to $62.00. They now have an “overweight” rating on the stock.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Monday, May 18th were paid a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, May 18th. Bio-Techne’s payout ratio is 46.38%.

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.